Literature DB >> 12586825

An Ile-568 to Asn polymorphism prevents normal trafficking and function of the human P2X7 receptor.

James S Wiley1, Lan-Phuong Dao-Ung, Changping Li, Anne N Shemon, Ben J Gu, Megan L Smart, Stephen J Fuller, Julian A Barden, Steven Petrou, Ronald Sluyter.   

Abstract

The P2X(7) receptor is a ligand-gated channel that is highly expressed on mononuclear cells and that mediates ATP-induced apoptosis of these cells. Wide variations in the function of the P2X(7) receptor have been observed, in part because of a loss-of-function polymorphism that changes Glu-496 to Ala without affecting the surface expression of the receptor on lymphocytes. In this study a second polymorphism (Ile-568 to Asn) has been found in heterozygous dosage in three of 85 normal subjects and in three of 45 patients with chronic lymphocytic leukemia. P2X(7) function was measured by ATP-induced fluxes of Rb(+), Ba(2+), and ethidium(+) into various lymphocyte subsets and was decreased to values of approximately 25% of normal. The expression of the P2X(7) receptor on lymphocytes was approximately half that of normal values as measured by the binding of fluorescein-conjugated monoclonal antibody. Transfection experiments showed that P2X(7) carrying the Ile-568 to Asn mutation was non-functional because of the failure of cell surface expression. The differentiation of monocytes to macrophages with interferon-gamma up-regulated P2X(7) function in cells heterozygous for the Ile-568 to Asn mutation to a value around 50% of normal. These data identify a second loss-of-function polymorphism within the P2X(7) receptor and show that Ile-568 is critical to the trafficking domain, which we have shown to lie between residues 551 and 581.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586825     DOI: 10.1074/jbc.M212759200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

Review 1.  A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases.

Authors:  Nishkantha Arulkumaran; Robert J Unwin; Frederick Wk Tam
Journal:  Expert Opin Investig Drugs       Date:  2011-04-21       Impact factor: 6.206

2.  A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization.

Authors:  Ying-Hong Feng; Xin Li; Liqin Wang; Lingying Zhou; George I Gorodeski
Journal:  J Biol Chem       Date:  2006-04-18       Impact factor: 5.157

Review 3.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

4.  Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures.

Authors:  Niklas R Jørgensen; Lise B Husted; Kristen K Skarratt; Leanne Stokes; Charlotte L Tofteng; Torben Kvist; Jens-Erik B Jensen; Pia Eiken; Kim Brixen; Stephen Fuller; Rory Clifton-Bligh; Alison Gartland; Peter Schwarz; Bente L Langdahl; James S Wiley
Journal:  Eur J Hum Genet       Date:  2012-01-25       Impact factor: 4.246

Review 5.  P2 receptors: intracellular signaling.

Authors:  Laurie Erb; Zhongji Liao; Cheikh I Seye; Gary A Weisman
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

6.  Cloning and pharmacological characterization of the guinea pig P2X7 receptor orthologue.

Authors:  E Fonfria; W C Clay; D S Levy; J A Goodwin; S Roman; G D Smith; J P Condreay; A D Michel
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

7.  Characterisation of the R276A gain-of-function mutation in the ectodomain of murine P2X7.

Authors:  Sahil Adriouch; Felix Scheuplein; Robert Bähring; Michel Seman; Olivier Boyer; Friedrich Koch-Nolte; Friedrich Haag
Journal:  Purinergic Signal       Date:  2009-02-21       Impact factor: 3.765

Review 8.  The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism.

Authors:  Guido Beldi; Keiichi Enjyoji; Yan Wu; Lindsay Miller; Yara Banz; Xiaofeng Sun; Simon C Robson
Journal:  Front Biosci       Date:  2008-01-01

Review 9.  Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states.

Authors:  D L Donnelly-Roberts; M F Jarvis
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

10.  Identification and characterization of a novel variant of the human P2X(7) receptor resulting in gain of function.

Authors:  Chengqun Sun; Jessica Chu; Sarita Singh; Russell D Salter
Journal:  Purinergic Signal       Date:  2009-10-17       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.